Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques [PDF]
npj Antimicrobials and ResistanceTuberculosis (TB) killed approximately 1.3 million people in 2022 and remains a leading cause of death from the bacteria Mycobacterium tuberculosis (M.tb); this number of deaths was surpassed only by COVID-19, caused by the SARS-CoV-2 virus. The alarming
Hazem F. M. Abdelaal +16 more
doaj +2 more sources
Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones Against Mycobacterium tuberculosis in Hainan, China [PDF]
PathogensOxazolidinones, novel synthetic antibacterials, inhibit protein biosynthesis and show potent activity against Gram-positive bacteria, including Mycobacterium tuberculosis (MTB).
Jinhui Dong +9 more
doaj +2 more sources
Sutezolid: A promising next generation tuberculosis agent
World Journal of Biology Pharmacy and Health SciencesSutezolid (PNU-100480) is an advanced oxazolidinone antibiotic that shows strong effectiveness against Mycobacterium tuberculosis, including those tough multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. It works by blocking bacterial protein synthesis, specifically by attaching to the 23S rRNA of the 50S ribosomal subunit, which ...
Kiran, Garlapati Usha +5 more
+5 more sources
Population Pharmacokinetic/Pharmacodynamic Analysis of the Bactericidal Activities of Sutezolid (PNU-100480) and Its Major Metabolite against Intracellular Mycobacterium tuberculosis in Ex Vivo Whole-Blood Cultures of Patients with Pulmonary Tuberculosis [PDF]
Antimicrobial Agents and Chemotherapy, 2014 ABSTRACT Sutezolid (PNU-100480 [U-480]) is an oxazolidinone antimicrobial being developed for the treatment of tuberculosis. An active sulfoxide metabolite (PNU-101603 [U-603]), which reaches concentrations in plasma several times those of the parent, has been reported to drive the killing of extracellular ...
Tong Zhu +3 more
openalex +2 more sources
Mycobacterium tuberculosis: Pathogenesis and therapeutic targets
MedComm, Volume 4, Issue 5, October 2023., 2023 In this review, we summarize the pathogenesis of TB infection, therapeutic targets, and corresponding modulators, including first‐line medications, current clinical trial drugs and molecules in preclinical assessment. Our review provides valuable insights for future antituberculosis drug development efforts.
Jiaxing Yang +3 more
wiley +1 more source
Advances in Key Drug Target Identification and New Drug Development for Tuberculosis
BioMed Research International, Volume 2022, Issue 1, 2022., 2022 Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of drug‐resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control. Therefore, there is an urgent need to develop new anti‐TB drugs to treat drug‐resistant TB and shorten the standard therapy.
Jie Mi +3 more
wiley +1 more source
Advances of capillary electrophoresis enantioseparations in pharmaceutical analysis (2017–2020)
ELECTROPHORESIS, Volume 42, Issue 17-18, Page 1709-1725, September 2021., 2021 Abstract Capillary electrophoresis is a powerful technique for the analysis of polar chiral compounds and has been widely accepted for analytical enantioseparations of drug compounds in pharmaceuticals and biological media. In addition, many mechanistic studies have been conducted in an attempt to rationalize enantioseparations in combination with ...
Sulaiman Krait +2 more
wiley +1 more source
The pipeline of new molecules and regimens against drug-resistant tuberculosis
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2021 The clinical development and regulatory approval of bedaquiline, delamanid and pretomanid over the last decade brought about significant progress in the management of drug-resistant tuberculosis, providing all-oral regimens with favorable safety profiles.
Todd A. Black, Ulrike K. Buchwald
doaj +1 more source
Culture-Free Enumeration of Mycobacterium tuberculosis in Mouse Tissues Using the Molecular Bacterial Load Assay for Preclinical Drug Development [PDF]
, 2022 BACKGROUND: The turnaround times for phenotypic tests used to monitor the bacterial load of Mycobacterium tuberculosis, in both clinical and preclinical studies, are delayed by the organism’s slow growth in culture media.
Clark, S +7 more
core +2 more sources
Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects
Molecules, 2021 This review covers the main aspects concerning the chemistry, the biological activity and the analytical determination of oxazolidinones, the only new class of synthetic antibiotics advanced in clinical use over the past 50 years.
Claudia Foti +3 more
doaj +1 more source